Benzinga | Jun 9, 2021 07:06AM EDT

TG Therapeutics To Present At 16th International Congress on Malignant Lymphoma Jun. 18-22

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 -- 22, 2021. Details of the data presentations are included below.



Poster Presentation Title TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies

* Abstract Book Number: 236

* Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST

* Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia

Poster Presentation Title Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma

* Abstract Book Number: 241

* Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST

* Lead Author: Ga?l Rou?, PhD, Lymphoma Translational Group leader, Josep Carreras Leukaemia Research Institute (IJC)

The above abstracts are now available in the 16th ICML abstract book, published online at https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2880. Additional information is available via the ICML meeting website at www.lymphcon.ch.

At the time of each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company's website at www.tgtherapeutics.com/publications.cfm